B.C. PharmaCare program approves additional drugs, expands coverage
Drugs now covered treat conditions including ulcerative colitis, Crohn's, migraines
The Ministry of Health says thousands of eligible British Columbians are benefiting from expanded coverage for medications that make it easier or more effective to treat their conditions.
A statement from the Health Ministry on Monday said B.C. PharmaCare has been rolling out new or expanded coverage for a range of medications since late last year.
The drugs treat conditions including ulcerative colitis and Crohn's disease, severely low blood sugar, migraines, low white blood cell levels, multiple sclerosis and heart failure.
The ministry said the new treatment covered for colitis or Crohn's disease can be administered by the patient rather than requiring a visit to a clinic, while a nasal spray is now available for the treatment of low blood sugar, or hypoglycemia, eliminating regular injections for thousands with that condition.
The ministry estimated at least 10,000 patients with migraines will gain from the addition of another drug to the official list of medicines, and the same number of patients with a specific type of heart failure will be eligible for a drug that dramatically cuts hospitalizations and the risk of death.
PharmaCare coverage has also been expanded to include what the ministry said is a long-acting, highly effective birth control drug that is implanted in the patient's upper arm as an alternative, low-cost option to birth control pills or intrauterine devices.
The drugs that are now covered or partly covered include:
- vedolizumab (Entyvio), used to treat moderately to severely active ulcerative colitis and Crohn's disease.
- a glucagon intranasal spray (Baqsimi) to treat severe low blood sugar reactions.
- fremanezumab (Ajovy) to treat chronic and episodic migraines.
- a filgrastim biosimilar (Nivestym) to prevent and treat low white blood cell levels.
- cladribine (Mavenclad) and siponimod (Mayzent) to treat multiple sclerosis.
- dapaglifozin (Forxiga) to treat of heart failure with reduced ejection fraction.
- etonogestrel (Nexplanon), a long-acting contraceptive implant.